Newsletter
Lupin said its subsidiary, Lupin Atlantis Holdings SA, has entered into a licensing and supply agreement with Galenicum Health.
Galenicum Health is a Barcelona-based pharmaceutical company founded in 2003. It works across the full pharma value chain, from R&D to manufacturing and commercialisation, and focuses on developing and supplying high-quality, affordable medicines and APIs.
Semaglutide, the active drug in Ozempic, is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for long-term weight management.
The deets: as per the agreement, Galenicum will handle the development, manufacturing, and supply of Semaglutide. Lupin will manage regulatory approvals, commercialisation, and distribution across 23 countries.
Why this matters: with this Semaglutide partnership, Lupin is strengthening its diabetes and obesity portfolio and expanding beyond India.
As diabetes cases rise globally, the collaboration positions the company to scale access to a critical therapy, reinforcing its focus on high-quality, affordable medicines and wider patient access at the right time.
ScanX.trade
